Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Co-administration of a thrombolytic and an anti-CD18 antibody in stroke

a technology of anticd18 and thrombolytic, which is applied in the field of anti-cd18 antibodies for treating stroke, can solve the problems of increasing cerebral blood flow, reducing the size of infarct, and serious problems for society

Inactive Publication Date: 2004-03-25
GENENTECH INC
View PDF9 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This presents a serious problem to society, with about 500,000 people dying from or becoming permanently disabled by stroke in the United States each year.
Preferably, the method results in an increase in cerebral blood flow and a decrease in infarct size resulting from the systemic hypoperfusion.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
  • Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
  • Co-administration of a thrombolytic and an anti-CD18 antibody in stroke

Examples

Experimental program
Comparison scheme
Effect test

example

[0128] This study investigated the effect of anti-CD18 antibody (MHM23) and t-PA in a rabbit model of thromboembolic stroke. In this model, a single blood clot is introduced into the middle cerebral and posterior communicating arteries (which are "main cerebral arteries"). The arterial obstruction (i.e., the clot) remains in place throughout the experiment (unless it is enzymatically removed by t-PA). The following rabbit model is thought to correlate well with the physiological progression of thromboembolic stroke in humans.

Materials and Methods

[0129] The rabbit model of thromboembolic stroke used in the current study has been previously described in detail (Bednar et al., Neurol. Res., 16:129-132 (1994); Gross etal., Stroke, 24:558-562 (1993); Kohut et al., Stroke, 23:93-97 (1992); Wilson et al., Neurosurgery, 31:929-934 (1992)). See, also, Gross et al., Neurosurgery, 36(6): 1172-1177 (1995).

[0130] Briefly, New Zealand white rabbits (Charles River, Calif.) (both males and females;...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and / or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.

Description

[0001] This application is a continuation of application Ser. No. 09 / 811,384, filed Dec. 20, 2000, claiming priority under 35 U.S.C. .sctn. 120 to non-provisional application U.S. Ser. No. 09 / 251,652, filed Feb. 17, 1999, which is a continuation-in-part application claiming priority under 35 U.S.C. .sctn. 120 to non-provisional application U.S. Ser. No. 08 / 788,800, filed Jan. 22, 1997, which claims priority under 35 U.S.C. .sctn. 119(e) to provisional application U.S. Serial No. 60 / 093,038, filed Jan. 23, 1996, (which was converted from non-provisional application U.S. Ser. No. 08 / 589,982 by petition), the entire disclosures of which non-provisional and provisional applications are incorporated herein by reference.[0003] 1. Field of the Invention[0004] This invention relates generally to the use of anti-CD18 antibodies for treating stroke. In particular, it relates to the use of anti-CD18 antibodies for improving clinical outcome by increasing cerebral blood flow and / or reducing inf...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/00A61K38/18A61K38/49A61K39/395C07K16/28
CPCA61K38/49A61K39/3955A61K2039/505C07K16/2821C07K16/2845C07K2316/96Y10S514/822C07K2317/54C07K2317/24A61K2300/00C07K2317/76A61P9/00
Inventor BEDNAR, MARTIN M.GROSS, CORDELL E.THOMAS, G. ROGERGROSS, LINDA
Owner GENENTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com